[Efficacy of exercise therapy to reduce cardiometabolic risk factors in overweight and obese children and adolescents: a systematic review]. / Wirksamkeit von Trainingsinterventionen zur Reduktion kardiometabolischer Risikofaktoren bei Kindern und Jugendlichen mit Übergewicht und Adipositas.

BACKGROUND AND OBJECTIVE: Excess weight in the younger population is associated with the various cardiovascular risk factors including hypertension, dyslipidemia and even metabolic syndrome early in life. Since these cardiometabolic profiles in children and adolescents track into adulthood they can give rise to the development of cardiovascular diseases and non-insulin-dependent diabetes. METHOD: A systematic literature search was performed in 4 electronic databases, Pubmed, PEDro, Cochrane Library und SPORTDiscus, looking for data on the efficacy of training programmes to improve cardiometabolic outcome parameters in overweight and obese children and adolescents. RESULTS: 12 randomized controlled trials were assessed eligible for inclusion. 9 of 12 trials documented improvements of at least one clinical or cardiometabolic marker in overweight children or adolescents upon completion of the training programme. CONCLUSION: Aerobic training programmes have the potential to effectively improve cardiovascular risk factors in overweight or obese children and juveniles. The evidence from previous studies is moderate. Further studies of high methodological quality are needed.

ECG signal analysis for the assessment of sleep-disordered breathing and sleep pattern.

The diagnosis of sleep-disordered breathing (SDB) usually relies on the analysis of complex polysomnographic measurements performed in specialized sleep centers. Automatic signal analysis is a promising approach to reduce the diagnostic effort. This paper addresses SDB and sleep assessment solely based on the analysis of a single-channel ECG recorded overnight by a set of signal analysis modules. The methodology of QRS detection, SDB analysis, calculation of ECG-derived respiration curves, and estimation of a sleep pattern is described in detail. SDB analysis detects specific cyclical variations of the heart rate by correlation analysis of a signal pattern and the heart rate curve. It was tested with 35 SDB-annotated ECGs from the Apnea-ECG Database, and achieved a diagnostic accuracy of 80.5%. To estimate sleep pattern, spectral parameters of the heart rate are used as stage classifiers. The reliability of the algorithm was tested with 18 ECGs extracted from visually scored polysomnographies of the SIESTA database; 57.7% of all 30 s epochs were correctly assigned by the algorithm. Although promising, these results underline the need for further testing in larger patient groups with different underlying diseases.

[Measuring sleep duration and sleep quality]. / Messung von Schlafdauer und Schlafqualität.

Restorative functions of sleep are of special interest for sleep medicine. For the assessment of these restorative functions, various parameters are taken into account, among which sleep duration and sleep quality play the most important roles. Both terms are essential for sleep perception, expressing the subjective satisfaction of the individual with the time spent asleep. In recent decades, sleep medicine and sleep research have developed methods for the assessment of both objective and subjective dimensions of sleep. Among subjective methods, taking of the medical history focusing on the patient's sleep is important. Standardized and validated questionnaires play a supportive role. Objective methods are, for example, estimation of the sleep-wake cycle by means of actigraphy and polygraphy. Especially in multimorbid patients, polysomnography is still the gold standard method for diagnostics. An important approach during recent years is shifting from bothering overnight examinations into less disturbing procedures for patients that include performing ambulatory, outpatient examinations in the patients' home rather than inpatient surveillance within sleep centers.

A prospective polysomnographic study on the evolution of complex sleep apnoea.

Complex sleep apnoea (CompSA) may be observed following continuous positive airway pressure (CPAP) treatment. In a prospective study, 675 obstructive sleep apnoea patients (mean age 55.9 yrs; 13.9% female) participated. Full-night polysomnography was performed at diagnosis, during the first night with stable CPAP and after 3 months of CPAP. 12.2% (82 out of 675 patients) had initial CompSA. 28 of those were lost to follow-up. Only 14 out of the remaining 54 patients continued to satisfy criteria for CompSA at follow-up. 16 out of 382 patients not initially diagnosed with CompSA exhibited novel CompSA after 3 months. 30 (6.9%) out of 436 patients had follow-up CompSA. Individuals with CompSA were 5 yrs older and 40% had coronary artery disease. At diagnosis, they had similar sleep quality but more central and mixed apnoeas. On the first CPAP night and at follow-up, sleep quality was impaired (more wakefulness after sleep onset) for patients with CompSA. Sleepiness was improved with CPAP, and was similar for patients with or without CompSA at diagnosis and follow-up. CompSA is not stable over time and is mainly observed in predisposed patients on nights with impaired sleep quality. It remains unclear to what extent sleep impairment is cause or effect of CompSA.

Ambulatory recording of sleep apnea using peripheral arterial tonometry.

Sleep related breathing disorders are common. A reliable diagnosis with relatively simple and portable methods is still needed. One approach is to make use of autonomous nervous system changes which accompany disordered breathing during sleep. The peripheral arterial tonometry (PAT) determines the peripheral arterial vascular tone using a plethysmographic method on the finger. The peripheral arterial tone is modulated by sympathetic activity, by peripheral blood pressure, and by the peripheral resistance of the vessels. We investigate a new ambulatory recording device which uses PAT, oximetry and actigraphy in order to detect sleep apnea. For this purpose we performed a comparative study on 21 patients referred to our sleep laboratory due to suspected sleep apnea. Of these 17 valid recordings were compared. The Watch-PAT was used in parallel with cardiorespiratory polysomnography and the validity was determined. The new system is able to detect apneas and hypopneas with a high reliability (r=0.89). It is very sensitive to arousals (r=0.77). Since arousal are not specific to sleep apnea the specificity of the new system could not be finally clarified in this study. We conclude that the new system is very well suited to perform control studies in patients with sleep apnea which are under therapy and require regular follow-up investigations to maintain a high CPAP compliance.

[Comorbidity in narcoleptic patients]. / Untersuchung zur Komorbidität bei Narkolepsiepatienten.

BACKGROUND AND OBJECTIVE: Narcolepsy is a rare disease which remains undiagnosed in 90 %. The international literature so far has paid little attention to comorbid disorders. PATIENTS AND METHODS: In preparation for a German Narcolepsy Register this pilot study evaluated data from hospital records of 106 narcolepsy patients (60 men, 46 women, 8-83 years, mean 45.1 years) retrospectively emphasising comorbid diseases. RESULTS: The parasomnias sleepwalking and nightmares were 6 times as frequent as in the general population. With respect to the HLA findings the extremely high frequency of REM behavior disorder contributes to the assumption of a common pathomechanism. Obstructive sleep apnea and periodic limb movement disorder (PLMD) occurred much less than described in literature, while the results on obesity, headache and depression are in line with published findings. CONCLUSION: Diagnosis of one of these comorbid disorders should always be followed by thorough investigation for symptoms of narcolepsy i. e. excessive daytime sleepiness, sleep attacks and cataplexy.

Association between blood pressure reduction with antihypertensive treatment and sleep apnea activity.

This study investigated whether a drug therapy-induced reduction in nocturnal blood pressure (BP) was associated with decreased sleep apnea activity. Two polysomnographies from 54 hospitalized male hypertensive, obstructive sleep apnea patients were analyzed in a double-blind, randomized, parallel-group trial of the angiotensin-converting enzyme inhibitor cilazapril (C), 2.5 mg once daily, or placebo (P). Blood pressure was measured by means of an intra-arterial catheter. Compared with P, C lowered mean arterial BP during non-rapid eye movement (NREM) (-8.3 +/- 10.7 mm Hg, P = .05) and REM sleep (-8.6 +/- 10.1 mm Hg, P = .02). Respiratory disturbance index (-8.6 +/- 3.2 events/h of sleep (n/h), P = .01) and apnea index (AI) (-6.6 +/- 3.0 n/h, P = .04) during NREM sleep were lowered by C and, to a lesser extent, by P (-5.9 +/- 3.2 n/h, P = .07 and -5.0 +/- 3.6 n/h, P = .18, respectively). The effect on AI and hypopnea index (HI) during REM sleep was not significant for C (-5.9 +/- 3.4 and 0.1 +/- 2.0, NS, respectively) and P (-2.6 +/- 3.9 and 1.6 +/- 2.0, NS, respectively). There was a significant linear correlation between the change in REM systolic BP and the change in REM AI (r = 0.28, P = .04); the mean BP change correlated negatively with the change in HI (-0.28, P = .04). During NREM sleep there was no significant correlation between changes in BP and the treatment effects on sleep apnea activity. Blood pressure reduction after short-term antihypertensive treatment did not affect sleep disordered breathing during NREM sleep. Reduced BP was associated with a weak reduction of AI and a slight increase of HI during REM sleep. It appears that elevated BP contributes only marginally to sleep apnea severity in hypertensive patients with obstructive sleep apnea.

Sleep-related breathing disorder is an independent risk factor for systemic hypertension.

The exact influence of sleep-related breathing disorder (SRBD) on blood pressure control remains unknown. We investigated the influence of different degrees of SRBD on daytime blood pressure and its association to documented hypertension by examining 1,190 consecutive patients referred for diagnosis of SRBD. The protocol includes clinical interview, physical examination, office blood pressure measurement, cholesterol, and blood gas analysis. Unattended home monitoring of nocturnal breathing was performed for assessment of SRBD activity (respiratory disturbance index [RDI]). RDI was independently and linearly associated with systolic blood pressure (unstandardized coefficient [B] = 0.07 +/- 0.03, p = 0.03), diastolic blood pressure (B = 0.07 +/- 0.02, p = 0 < 0.001), and heart rate (B = 0.10 +/- 0.02, p < 0.001) at rest. The relative risk for hypertension (blood pressure >/= 160/95 mm Hg) increased with SRBD severity (odds ratio [OR], 4.15 for RDI >/= 40 versus < 5 [95% CI, 2.7 to 6.5]). This relative risk was also elevated in younger ( 50 yr) (OR, 7.15 versus 2.70 for RDI >/= 40 versus < 5). These cross-sectional clinical data suggest a relationship between SRBD severity and systolic blood pressure, diastolic blood pressure, and heart rate after control for confounders such as body mass index (BMI), age, alcohol/nicotine consumption, cholesterol level, and daytime PO(2) and PCO(2). SRBD is an independent risk factor for systemic hypertension with an increased likelihood in subjects

[Actigraphy: methodological limits for evaluation of sleep stages and sleep structure of healthy probands]. / Aktigraphie: Methodische Begrenzungen für die Beurteilung von Schlafstadien und Schlafstruktur gesunder Probanden.

UNLABELLED: Purpose of the investigation was to evaluate the differences of movement density during the sleep stages and waking. 22 diurnally active, healthy, male volunteers of mean age 30.7 (+/-Standard deviation +/- 3.3) years and a Body-Mass-Index 23.6 +/- 3.3 kg/m2 participated in the study. All subjects were recorded in the sleep lab via cardiorespiratory polysomnography and wrist actigraphy (Ambulatory Monitoring, Ardsley, USA) worn on the non-dominant hand, for two consecutive nights. The activity data, consisting of the number of zero crossings (NZC) were recorded in 1-minute periods. Sleep stages were scored visually according to standard criteria. EEG- and actigraphy data were converted to the same data format (European Feature Files). Attaching the actimetry data to the sleep stages was calculated mean NZC for every sleep stage and Wake. In spite of high differences in total individual NZC we observed that most NZC occurred during Wake. NREM 1 movement density was significantly higher in 19 recordings (86%) than in any other sleep stage. In 18 cases (82%) lowest movement density was found in NREM 3/4 with significant difference to all other sleep stages. Within 50% of the recordings were found decreasing activity in the following sequence of stages: Wake > NREM 1 > REM > NREM 2 > NREM 3/4 However, in all other cases there was a varying pattern of activity. CONCLUSION: Although there is some correlation between motor activity and sleep stages, the predictive value of actimetry data analysis in the assessment of sleep structure appeared to be limited mainly by individual movement density, especially during REM and NREM 2.

[Use of discontinuous long-term blood pressure measurement (Spacelabs 90207) in patients with sleep apnea--a comparison with intra-arterial data]. / Der Einsatz der diskontinuierlichen Langzeitblutdruckmessung (Spacelabs 90207) bei Patienten mit Schlafapnoe--ein Vergleich der Methode mit intraarteriellen Daten.

Circadian blood pressure (BP) profile is an important determinant of cardiovascular risk. Patients with Sleep-Related Breathing Disorders (SRBD) often suffer from arterial hypertension and an altered circadian blood pressure profile. The aim of this study was to compare intraarterial blood pressure recordings with DBPR (Discontinuous Blood Pressure Recorder using Spacelabs 90207) in 20 patients with mild to moderate arterial hypertension and mild to moderate SRBD. Our results of overnight measurements show that the mean arterial pressure seems to be the most reliable value (mean difference Spacelabs-Part: +1.7 mmHg). In contrast, the systolic BP was systematically underestimated (mean: -17.5 mmHg) while the diastolic value was systematically overestimated (mean: +9.3 mmHg) by Spacelabs. Our data show that neither systolic nor diastolic BP from the Spacelabs measurement reflected the real cardiovascular load. Since the mean arterial pressure proved to be the most reliable value, this value should be used to distinguish between dipper and non-dipper in circadian BP profiles. Further, reliable noninvasive continuous measurement of the BP is required to assess the real vascular load in patients with SRBD during the night.

[Increased daytime tiredness, nocturnal hypertension and sleep apnea: studies in rural general practice]. / Gesteigerte Tagesmüdigkeit, nächtliche Hypertonie und Schlafapnoe: Untersuchungen in einer Landarztpraxis.

Studies in a Rural General Practice: Sleep-Related Breathing Disorders (SRBD) and altered circadian blood pressure profile are related to increased cardiovascular risk. We investigated the prevalence and coincidence of both diseases in male patients from a general practice in a small community of 2500 people. Out of 409 selected patients (using a questionnaire regarding symptoms and findings of SRBD), 185 were monitored in an outpatient setting with an apnoea-screening system Mesam IV. Ambulatory blood pressure monitoring (Spacelabs 90207). Holter-ECG and actigraphy were also measured. Sixty patients had a Respiratory Disturbance Index (RDI) > 10. An indication for further sleep studies was seen in 40 patients; 36.5% of daytime hypertensives were "Non-Dipper", and 47.6% of normotensives were also "Non-Dipper". Excessive daytime sleepiness (EDS) is an important symptom of SRBD, and in this investigation we noticed a large number of patients without this symptom suffering from relevant SRBD. Therefore, absence of EDS alone is not indicative for the use of ambulatory monitoring.

Effect of angiotensin converting enzyme inhibition [Cilazapril] on blood pressure recording in hypertensive obstructive sleep apneic patients.

We investigated the efficacy of an Angiotensin Converting Enzyme [ACE] inhibitor on daytime and night-time blood pressure in 55 male hypertensive patients with moderately severe to severe obstructive sleep apnea. We resolved to determine if treatment oriented towards the reduction of hypertension would be successful, despite persistent repetitive hypoxemia and sleep-disordered breathing. The study was a randomized, double-blind, single daily dose, placebo-controlled protocol, with 8 days drug intake (placebo or 2.5 mg Cilazapril) and monitoring on the final day of drug administration. Subjects underwent continuous 24-h arterial blood pressure monitoring during baseline and treatment conditions. Polysomnography was performed at night during the 24-h arterial monitoring period. Cilazapril (2.5 mg) lowered systolic, diastolic and mean blood pressure, despite persistence of repetitive obstructive apneas during sleep and the associated repetitive hypoxemia. The lowering of blood pressure occurred without a significant change in heart rate, and was noted during nocturnal sleep, performance testing and graded exercise.

Sleep-related myocardial ischemia and sleep structure in patients with obstructive sleep apnea and coronary heart disease.

STUDY OBJECTIVES: Patients with coronary heart disease (CHD) and obstructive sleep apnea may have an increased cardiac risk due to nocturnal myocardial ischemia triggered by apnea-associated oxygen desaturation. Sleep structure in patients with obstructive sleep apnea is fragmented by activation of the central nervous system (CNS) (arousal) due to obstructive apneas. Nocturnal myocardial ischemia may lead to activation of the CNS as well. PATIENTS: Fourteen patients with obstructive sleep apnea and CHD disease and seven patients suffering from obstructive sleep apnea without CHD were studied. Overnight sleep studies and simultaneous six-lead ECG recordings were performed. In addition, sleep studies and ECG recordings were performed with administration of a sustained-release nitrate in these patients in a double-blinded crossover design. RESULTS: Analysis of three nights' recordings revealed 144 episodes of nocturnal myocardial ischemia in six subjects. Five patients had underlying CHD and one patient exhibited diffuse wall defects of the coronary arteries; also, 85.4% of ischemic episodes were concomitant with apneas and oxygen desaturation > 3%, and 77.8% of ischemic episodes occurred during rapid eye movement (REM) sleep, although total amount of REM sleep was only 18% of total sleep time. Mean oxygen saturation was significantly lower (p < 0.05) during apnea-associated ischemic episodes than during nonapnea-associated ischemia (77.3% vs 93.1%). Nitrate administration did not reduce ischemic episodes. Sleep architecture (macrostructure) exhibited a reduction in sleep stages non-REM 3 and 4 and REM sleep. Comparing the microstructure of sleep (arousals) within episodes with and without ischemia but similar criteria like sleep stage, apnea activity, and oxygen saturation, we found significantly more (p < 0.01) and severe (p < 0.001) arousals during periods with myocardial ischemia than during control episodes. In addition, microstructure of sleep was disturbed by myocardial ischemia itself in absence of apneas. CONCLUSION: It is concluded that patients with CHD and obstructive sleep apnea are endangered by apnea-associated ischemia and that these ischemic episodes lead to activation of the CNS and additional fragmentation of sleep. Patients with nocturnal ischemia should be screened for underlying sleep apnea even if nitrate therapy fails.

Risk of traffic accidents in patients with sleep-disordered breathing: reduction with nasal CPAP.

Sleepiness whilst driving constitutes a road safety risk. Sleep-related breathing disorders are the most frequent medical cause of daytime sleepiness, and untreated patients with this condition have been shown to be at a higher risk of having accidents while driving. This study addressed the question of the extent to which treatment of sleep-disordered breathing by nasal continuous positive airway pressure (nCPAP) is related to changes in patient's accident risk. Seventy eight male patients requiring treatment of sleep-related breathing disorders with nCPAP were enrolled in the study. The protocol included a questionnaire dealing with alertness-related problems while driving, an 80 min vigilance test, and the Multiple Sleep Latency Test. These baseline evaluations were repeated after 1 year of treatment with nCPAP. Fifty nine patients completed the study. The accident rate was significantly decreased from 0.8 per 100,000 km (untreated) to 0.15 per 100,000 km with nCPAP treatment. Variables that were considered to be likely to increase accident risk (sleeping spells, fatigue, vigilance test reaction time, daytime sleep latency) also improved with treatment. We conclude that treatment of sleep-disordered breathing by nasal continuous positive airway pressure is related to reduction in patient motor vehicle accident rates, probably due to the reversal of excessive daytime sleepiness.

Unattended continuous positive airway pressure titration. Clinical relevance and cardiorespiratory hazards of the method.

The high cost of in-laboratory sleep studies and the insufficiency of available nights in most sleep laboratories has prompted clinical trials in an attempt to find an effective and safe method for continuous positive airway pressure (CPAP) titration in the unsupervised home environment. Earlier publications focused on the effectiveness of this new method but did not indicate the potential hazard and the selection criteria of patients. We accomplished a prospective study to evaluate a machine-controlled CPAP titration method in an unselected group of 21 patients with obstructive sleep apnea (OSA) requiring CPAP therapy. Unattended CPAP titrations were completed in the sleep laboratory, followed by conventional CPAP titration night. The CPAP levels assessed through automatic titrations showed strong agreement with those from the control nights. Fifteen patients had no pathologic cardiorespiratory events during machine-controlled titration. Undesirable cardiorespiratory complications developed in six patients with underlying cardiorespiratory disorder. Two patients had to stop the procedure. Two patients needed a reset of the actual pressure to baseline because of central apneas and one patient because of high-grade arrhythmia. The machine-controlled CPAP titration enabled reliable assessment of an effective pressure and appeared to be safe in selected patients with OSA. However, because the method caused significant adverse effects in some patients, we recommend that unattended CPAP titration not be attempted in patients with underlying cardiorespiratory disease.

[Risk of accident due to hypersomnia: relevance for sleep medicine]. / Unfallrisiko durch Hypersomnien: Bedeutung für die Schlafmedizin.

Hypersomnia is increasingly recognized as a potential causal factor for accidents. Information of the general public about scientific knowledge on the area of fatigue and sleepiness is, as well as the recognition and treatment of disorders impairing vigilance, an important task for sleep medicine. Fulfilling this task will warrant an important contribution to increase road safety. Sleep related disordered breathing is an example that shows the sense and the need for a qualitatively good medical care of patients with sleep related disorders.

REM-sleep-hypertension in obstructive sleep apnea.

Previous investigations involving continuous blood pressure (BP) monitoring have shown an important alteration of the 24-hour BP profile in patients with obstructive sleep apnea syndrome (OSAS). We investigated the impact of REM sleep on the 24-hour BP cycle in 16 severe OSAS male patients (mean respiratory disturbance index = 66 +/- 16 events/hour of sleep), with hypertension (mean BP 162 +/- 21/105 +/- 11 mmHg World Health Organization (WHO) protocol). Two successive nights of polysomnography were performed, and arterial BP was monitored continuously during the second 24-hour period after brachial artery cannulation. During the daytime, subjects were kept awake and supine. At 3 p.m. BP was continuously monitored during quiet supine wakefulness for 20 minutes. Systolic, diastolic and mean BP and heart rate (HR) were analyzed and tabulated in mean values of 5 minute segments. Sleep/wake information were correlated with cardiovascular variables. Each uninterrupted REM sleep period was identified and comparison between the period of quiet supine wakefulness and REM sleep HR and BP values was performed. 8 OSAS patients presented a normal drop of the mean arterial BP during the nocturnal REM sleep periods compared to quiet supine wakefulness (mean value = -10.8 +/- 7.3 mmHg) ("dippers") while the other 8 subjects ("REM sleep non dippers"), revealed an elevated mean arterial BP during REM sleep (mean value = 18.9 +/- 10.9 mm Hg). The absence of the normal circadian BP dip seen during the nocturnal sleep period is considered as an indication of vascular risk. The REM sleep non dipping may play a role in this risk.

Arterial hypertension and sleep apnoea: effect of the angiotensin-converting enzyme (ACE) inhibitor cilazapril on continuously measured blood pressure during sleep and wakefulness.

Male patients with arterial hypertension and obstructive sleep-related breathing disorders (mean age 50 y, Body Mass Index (BMI) 32.4 kg m-2, Respiratory Disturbance Index (RDI) 47.2 and systolic/diastolic blood pressure (SBD/DBD) 162/103 mmHg) were examined before and after 8 days of treatment with the long-acting angiotensin-converting-enzyme (ACE) inhibitor cilazapril 2.5 mg vs. placebo in a double-blind design with parallel groups. Cardiorespiratory polysomnography was carried out at night; during daytime wakefulness patients submitted to examinations of physical and mental exertion. Cilazapril reduced the mean pressure during the entire examination period (day and night) by 9.55 (SD +/- 7.13) mmHg, compared to 4.57 (SD +/- 7.20) mmHg for placebo (P < 0.006), independently from systematic changes of heart rate (x = -3.3 and -3.5 bpm, respectively). During REM sleep, mean arterial pressure was significantly reduced by 8.63 (SD +/- 10.1) mmHg, compared to a reduction on placebo of 3.17 (SD 9.6) mmHg (P = 0.023). Under psychometric strain, the mean arterial pressure was reduced by 15.31 (SD +/- 8.7) mmHg with cilazapril; under placebo medication by 6.19 (SD +/- 7.3) mmHg (P < 0.0001). Heart rate was not significantly changed.

Intrathoracic pressure changes and cardiovascular effects induced by nCPAP and nBiPAP in sleep apnoea patients.

The effect of nasal continuous positive airway pressure (nCPAP) and nasal bi-level positive airway pressure (nBiPAP) on intrathoracic pressure and haemodynamics during wakefulness was studied in a group of nine patients with severe sleep apnoea. No patient took cardiovascular medication. Patients were studied with a Swan Ganz catheter, an arterial line and an oesophageal balloon. nCPAP and nBiPAP were applied in the following pressure sequence: 5, 10 and 15 cm H2O of CPAP and 10/5 and 15/10 cm H2O of nBiPAP. Measurements were made at the end of a 5-min period at each pressure level. Intrathoracic pressure was noted to increase to a level of approximately 50% of the pressure delivered at the mask. At a CPAP of 10 cm H2O and above, as well as at BiPAP of 10/5 or higher, there was a decrease in cardiac output (CO) and cardiac index (CI). CI fell below the normal value in two of the patients. Transmural pulmonary artery pressure (PPAtm) decreased at a CPAP of 15 cm H2O and at both BiPAP levels. Transmural right atrial pressure (PRAtm) decreased at both BiPAP levels. There were no differences in CO, CI, PPAtm and PRAtm between nCPAP and nBiPAP at equal inspiratory pressures. SaO2 increased during BiPAP 15/10 cm H2O, whereas heart rate and arterial blood pressure did not change significantly. The data presented here are consistent with the literature on positive end-expiratory pressure (PEEP) applied via intratracheal tube and are likely to be due to a reduced venous return. It is concluded that nasally applied positive pressure may have acute negative effects on cardiac function in patients with sleep apnoea.

Coronary heart disease and upper airway obstruction.

Coronary heart disease (CHD) is a leading cause of death among middle-aged men. In the same age group the spectrum of upper airway obstruction from habitual snoring to obstructive sleep apnoea syndrome (OSAS) is frequent. In several studies snoring was found to be an important risk factor for ischaemic heart disease. The prevalence of OSAS in patients with CHD, profile of risk factors and ventricular arrhythmias was determined in a prospective manner in 78 patients with stenosis of one or more coronary arteries at coronary arterography. OSAS was found in 27 patients (34.6%). Mean respiratory disturbance index (RDI) was 23.9. RDI increased with higher age. No significant differences in both groups could be found in ventricular arrhythmias, left ventricular ejection fraction and risk factors, except hyperuricaemia and adiposity. OSAS is frequent in patients with CHD and may be an additional risk factor besides the known coronary risk factors. Patients with the combination of CHD and OSAS have to be regarded as a group at particular risk because of several interactions between OSAS and coronary haemodynamics. Furthermore the microstructure of sleep in patients with nocturnal myocardial ischaemia is disturbed.